RMC No. 62-2025: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, High Cholesterol, Mental Illnesses, and Tuberculosis

RMC No. 62-2025 updates VAT-exempt medicines for key diseases, requiring pharmacies and healthcare sellers to verify FDA publication and product tax codes. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of covered medicines must immediately check the latest FDA-published VAT-exempt medicines list before issuing invoices, pricing products, or claiming VAT treatment. RMC No. 62-2025 confirms […]

RMC No. 25-2025: FDA Updates to VAT-Exempt Medicines for Diabetes, Hypertension, High Cholesterol, and Mental Illness

RMC No. 25-2025 confirms FDA updates to VAT-exempt medicines for diabetes, hypertension, high cholesterol, and mental illness under TRAIN and CREATE. Businesses selling, purchasing, distributing, or accounting for medicines covered by the FDAโ€™s updated VAT-exempt list must immediately review their product master files, invoicing settings, and VAT treatment because the VAT exemption takes effect upon […]

RMC No. 100-2024: FDA-Endorsed Updates to VAT-Exempt Medicines for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, and Tuberculosis

RMC No. 100-2024 publishes FDA updates to VAT-exempt medicines and confirms exemption applies from the FDA publication date of the updated list. Businesses selling, purchasing, prescribing, distributing, or accounting for covered medicines must immediately check whether their products are included in the updated FDA-endorsed list of VAT-exempt products, because VAT exemption under RMC No. 100-2024 […]

RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RMC No. 125-2022: Updated FDA List Deletes Certain COVID-19 Treatment Medicines from CREATE Act VAT Exemption

RMC No. 125-2022 updates the FDA VAT-exempt medicines list, deleting certain COVID-19 treatment medicines under the CREATE Act. Businesses selling, purchasing, importing, distributing, prescribing, or accounting for medicines used in COVID-19 treatment must immediately re-check the current FDA-published List of VAT-Exempt Medicines before treating those medicines as VAT-exempt. RMC No. 125-2022 makes a critical update […]

RMC No. 83-2022: Updated VAT-Exempt Medicines List for Diabetes, Hypertension, Mental Illness, Cancer, and Kidney Disease Drugs

RMC No. 83-2022 updates the VAT-exempt medicines list under CREATE, covering diabetes, hypertension, mental illness, cancer, and kidney disease drugs. Businesses that manufacture, import, distribute, sell, prescribe, dispense, procure, or account for medicines must immediately review their VAT treatment because RMC No. 83-2022 confirms updates to the List of VAT-Exempt Medicines under Republic Act No. […]